RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog



439 Features

23 Aug 04

Eventually, methods developed by research laboratories need to be transferable to face the rigours of external validation or the production line. Many researchers, however, are unaware that this procedure must be adequately documented, a crucial issue when it comes to regulation and outsourcing.
Rachel Holdsworth/Geoff Pulham

It's not just drug discovery that's an expensive business

23 Aug 04

Pharmaceutical practices from manufacturing to marketing are coming under increasing scrutiny from watchdogs, regulators and shareholders. As huge fines and record settlements erode profits, Datamonitor's Andrew Jones argues that pharma companies must focus on tightening compliance...

Researchers report on the role of estrogen in airway function: Can menopause accelerate the progression of COPD?

19 Aug 04

DailyUpdates 18th August, 2004: Recent data suggest that women may be more susceptible to the chronic airway disorders emphysema and bronchitis, together known as chronic obstructive pulmonary disease (COPD). The reasons for this are unclear however data published this month demonstrate a key role of the estrogen receptor in maintaining alveolar surface area and airway elasticity. This suggests that menopause may contribute to the acceleration of COPD and prompts investigation into the develop

Can you Sell Yourself?

18 Aug 04

After my many years of conducting interviews and recruiting for both junior and senior employees, I have come to the conclusion that if there is one single thing that a person can do to secure a second interview or a desired position it is believe in themselves.
Susan Mason

Proteolytic beta amyloid light chain antibody fragments offer promise as future treatments of Alzheimer’s disease.

17 Aug 04

DailyUpdates 18th August, 2004: Researchers from at Arizona State University have demonstrated that beta amyloid light chain proteolytic antibody fragments can cleave beta-amyloid, altering the aggregation and neutralizing the cytotoxic effects of this peptide.

Antibody-drug conjugates offer hope for the treatment of hormone resistant prostate cancer

17 Aug 04

DailyUpdates 17th August, 2004: Researchers from Protein Design Laboratories report that an antibody-drug conjugate that links the chemotherapeutic agent Auristatin to a prostate cancer specific antibody, anti-TMEFF2 mAb, via a cathepsin B-sensitive linker prevents tumor growth in a murine model of prostate cancer.

New rhinitis therapy should help patients to breathe easy

13 Aug 04

Rigel's new intranasal inhibitor R112 could offer a useful alternative therapy for patients suffering from allergic rhinitis, as Datamonitor's Shaun Falkingbridge explains. Bolstered by supportive recent trial results, Rigel can now go on to seek partner firms to realize full commercialization of the drug...

US online pharmacies can attract consumers from cross-border discounters

12 Aug 04

The trade in discounted prescription drugs between Canada and the US has elicited considerable controversy on both sides of the border. Yet recent figures show that sales of drugs via Canadian pharmacies have not been as great as some had predicted. However, as Datamonitor's David Deon explains, pharmaceutical companies could go further by driving the expansion of online prescribing in the US...

Big bucks battling super bugs?

03 Aug 04

Bacterial skin diseases like gangrene can now expect an onslaught of new specialist medications. However, skin infections make up a relatively small proportion of the $20.4 billion annual global antibacterial market, which, says Datamonitor's Amber Gibson, raises questions about why such conditions are the current focus of so much antibacterial product development...

Pharmaceutical companies set to make a significant profit from anti-obesity drugs

26 Jul 04

By 2012, the anti-obesity drugs market will be worth an estimated $2.5 billion globally, compared to $526 million today. However, new drugs will not be the answer to the growing obesity problem. Datamonitor's Jasjeet Mohain argues that increasing education and awareness of the importance of good diet and exercise will remain crucial to combating obesity...

Roche's Fuzeon offers the 20% of patients that receive it

19 Jul 04

New clinical research presented at the 15th International AIDS Conference (IAC) shows that Fuzeon is proving to be remarkably effective in the first long-term trial of its benefits.

Advances in the development of corticotropin-releasing-hormone (CRH) receptor agonists as candidate analgesics

13 Jul 04

Acute pain resulting from conditions such as headache, muscle spasms, dental problems or following surgery, affects 90 million Americans every year. A recent study has demonstrated the analgesic activity of corticotropin-releasing-hormone (CRH) and has shown that this activity is probably due to activity within the central nervous system.

The emerging role of the IL-4/IL-3 cytokine receptor IL-4Ralpha in asthma

09 Jul 04

Analysts have recently predicted that the market for airway inflammatory diseases will increase by 35% to over $18 billion by 2011. A recent target evaluation report produced for the drug development sector concluded that the TH2-derived cytokines IL-4, and more so IL-13 represent promising targets. Both cytokines activate IL-4Ralpha to produce multiple functional changes observed in asthma patients. A recent report published in the Journal of Immunology elucidates the divergent mechanisms th

Strong potential for cross risk-factor single pill therapies

09 Jul 04

Recently published data from the GENOA study has demonstrated that dyslipidemia is highly prevalent in hypertensive adults and that this condition is insufficiently treated in more than half of the cases. As Datamonitor's Laurent Chanroux explains, the results lend further support to cross risk-factor, single pill combination therapies such as Pfizer's Caduet...

Early adopters of ePrescribing serve as models in a growing market

05 Jul 04

SureScripts, in partnership with the Massachusetts Medical Society, is launching an educational network providing physicians with information from the early adopters of ePrescribing technology. Datamonitor's Kimberly O'Malley argues that educational forums like this allow members to more efficiently evaluate and subsequently adopt electronic prescribing as a solution for their practices...


05 Jul 04

Metabolic syndrome, a cluster of common metabolic disorders including obesity, pre-diabetes, abnormal lipid levels and high blood pressure, is now approaching epidemic proportions worldwide.

Emerging Drug Discovery Targets; June 28th

29 Jun 04

This edition of "Emerging Drug Discovery Targets" features new approaches to improving intestinal uptake of poorly absorbed therapeutics; a dual 5-LO inhibitor/H1 receptor antagonist for the treatment of asthma; Sitaxentan as an effective treatment of pulmonary arterial hypertension; Kv1.3 potassium channel blockade as an approach to insulin resistance; Drug delivery technology predicted to allow safer and more effective use of steroids in the treatment of rheumatoid arthritis; VEGF receptor tyr

Novartis’/Schering’s VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584 as a candidate treatment of rheumatoid arthritis.

25 Jun 04

Rheumatoid arthritis is one of the more common autoimmune diseases. LeadDiscovery’s recent state of the art evaluation of rheumatoid arthritis therapeutics evaluates advances in our understanding of the etiology of the disease. One field of research extensively analyzed in this report is angiogenesis. Inhibitors of receptor tyrosine kinase with specific activity against the VEGFRs have been developed in an attempt to prevent angiogenesis. One such molecule is PTK787/ZK222584, synthesized and dev

Drug delivery technology predicted to allow safer and more effective use of steroids in the treatment of rheumatoid arthritis

23 Jun 04

An estimated 5 million individuals suffer from rheumatoid arthritis. Corticosteroids are the most dramatically effective short-term anti-inflammatory drugs; however, clinical benefit for rheumatoid arthritis often diminishes with time. Because of their long-term systemic side effects, corticosteroids are usually given only after a careful and prolonged trial of less hazardous drugs. Liposomes are artificial vesicles efficiently phagocytosed by macrophages and recent advances such as the developm

Kv1.3 potassium channel blockade as an approach to insulin resistance

22 Jun 04

The R&D activity surrounding novel oral treatments of diabetes is considerable and one particular target that has recently received attention is the Kv1.3 potassium channel. Blocking this channel has been thought to be of value in the treatment of multiple sclerosis and more recently for preventing weight gain. Now researchers from Yale have demonstrated that Kv1.3 channel blockers may also increase insulin sensitivity in genetically obese and diabetic mice

Sitaxentan as an effective treatment of pulmonary arterial hypertension

21 Jun 04

Pulmonary arterial hypertension (PAH) represents an unmet market. Initial breakthroughs in treatment focussed on the rare form of this condition, idiopathic pulmonary arterial hypertension. Recently however a key advance in the treatment of PAH was made with the launch of Actelion's twice-daily Tracleer (bosentan) as the first orally active treatment of both idiopathic and secondary PAH. Tracleer is the first generation of a class of drugs known as endothelin receptor antagonists and blocks two

The development of a dual 5-LO inhibitor/H1 receptor antagonist for the treatment of asthma

20 Jun 04

Numerous inflammatory mediators have been implicated in the etiology of asthma. Blocking specific inflammatory mediators has frequently yielded unimpressive clinical results and instead the simultaneous targeting or more than one mediator may be of greater use. In the current edition of LeadDiscovery's TherapeuticAdvances work by researchers at UCB who have developed a dual 5-LO inhibitor/H1 receptor antagonist is highlighted

PABORD - dedicated to Outsourcing in Research and Development

17 Jun 04

PABORD is the first exhibition and conference dedicated to Outsourcing in Research and Development for the Pharmaceutical and Biotechnology industries.
Simon Berger

Pharma NewsBytes: June 16th, 2004

16 Jun 04

Pharma NewsBytes selects out some of the most interesting press releases to have appeared on LeadDiscovery’s DailyUpdates tracking service over the past few weeks. This edition includes an update on selected releases from the American Society of Clinical Oncology and the American Diabetes Association as well as important news concerning the antipsychotic, Abilify (Aripiprazole) and novel HIV treatments

Biogenerics market presents new commercial opportunity

11 Jun 04

With several blockbuster biological products approaching patent expiry and the emergence of new approval pathways, the biogenerics segment represents an attractive opportunity for companies looking to escape intensifying competition in the commodity generics sector. However, with the biotech industry preparing significant opposition to any new regulatory initiatives, barriers to market entry could remain high.

Lilly’s pemetrexed (Alimta) offers potential improvements in the treatment of non-small cell lung cancer (NSCLC)

20 May 04

DailyUpdates 20th April: Nearly 423,000 new cases of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are expected to have been diagnosed in the seven major pharmaceutical markets in 2003. Despite the high level of pharmaceutical interest, there are significant unmet needs in the disease in terms of poor survival. Docetaxel is the only drug currently approved in both the U.S. and Europe to treat patients with non-small cell lung cancer in the second-line setting. While the dr

NicOx’s nitro-derivative of naproxen, HCT 3012, shown to be effective in a model of myocardial infarction

11 May 04

DailyUpdates 11th May: A number of clinical studies including the VIGOR trial have suggested that the NSAID naproxen may reduce the incidence of myocardial infarction. However the gastrointestinal side-effects of naproxen and its ability to exacerbate hypertension preclude its use in at-risk individuals. Upcoming data about to be published in the journal JPET demonstrate the efficacy of the safer and anti-hypertensive nitro-derivative of naproxen, HCT 3012, in a model of myocardial infarction.

Emerging Drug Discovery Targets 6th May

06 May 04

This edition of Emerging Drug Discovery Targets features MBD2 inhibitors as a selective strategy for reducing tumor growth; NicOx's NO-ASA cancer candidate, NCX 4040, MIF as a target for atherogenesis; expanding indications for COX-2 inhibitors; and a dual MMP and TACE inhibitor as a treatment of rheumatoid arthritis. This edition also sees a new section "TherapyUpdate" which this month focuses on Osteoporosis. As usual we also provide updates on industrial advances and licensing opportunities a